Predict individual Parkinson disease progression
- Trial ID
- NCT05065060
- Official Title
- Parkinson's Progression Markers Initiative Online Study (PPMI Online)
- Goal
- Predict individual Parkinson disease progression
- Status
- RECRUITING
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Study Type
- OBSERVATIONAL
- Enrollment
- 500000 participants
- Conditions
- Parkinson Disease
- Interventions
- Observation
Summary For Families
PPMI Online aims to find biomarkers and patterns that show when Parkinson's starts and how it progresses, so researchers can detect early signs and track disease course more accurately. The approach is observation only, with participants completing online questionnaires and periodic remote assessments so researchers can analyze symptom, health, and lifestyle data over time. Adults 18 and older can join, whether they have a Parkinson's diagnosis or not, and the study is enrolling a large, remote cohort to make findings more representative. The Michael J. Fox Foundation is running the project and plans to enroll up to 500,000 people.
Locations
- UCSF Movement Disorders and Neuromodulation Center (MDNC), San Francisco, California, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Observation. PPMI Online aims to find biomarkers and patterns that show when Parkinson's starts and how it progresses, so researchers can detect early signs and track disease course more accurately. The approach is observation only, with participants completing online questionnaires and periodic remote assessments so researchers can analyze symptom, health, and lifestyle data over time. Adults 18 and older can join, whether they have a Parkinson's diagnosis or not, and the study is enrolling a large, remote cohort to make findings more representative. The Michael J. Fox Foundation is running the project and plans to enroll up to 500,000 people.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 20 years and 4 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.